⌕
Adaptive Biotechnologies · ADPT · Nasdaq
Tenet 42 · Weak
Compare
$27.87−4.03%At closeTenet 42 · Weak
$27.87−1.17 (−4.03%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Adaptive Biotechnologies (ADPT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 10, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive…

● Zacks Investment ResearchNov 10, 2026 · 10:16 ET
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.…

● Defense WorldNov 6, 2026 · 02:15 ET
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm, MarketBeat.com reports. O…

● Seeking AlphaNov 4, 2026 · 21:24 ETEARNINGS EXPECTED BY FEB 9
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript…

● Zacks Investment ResearchNov 4, 2026 · 20:51 ETEARNINGS EXPECTED BY FEB 9
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a year ago.…

● Zacks Investment ResearchNov 4, 2026 · 20:01 ETEARNINGS EXPECTED BY FEB 9
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimat…

● MarketBeatNov 4, 2026 · 19:30 ETEARNINGS EXPECTED BY FEB 9
Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in b…

● GlobeNewsWireNov 4, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 9
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive i…

● Seeking AlphaOct 27, 2026 · 10:16 ET
Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

Adaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to $66.2M, with clinica…

● Defense WorldOct 27, 2026 · 04:13 ET
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the business's stock in a transaction on Friday, October 23rd. The shares were sold at an average price of …

● Defense WorldOct 27, 2026 · 04:13 ET
Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the firm's stock in a transaction on Monday, October 26th. The stock was sold at an average price of $26.04…

● Seeking AlphaOct 23, 2026 · 14:23 ETEARNINGS EXPECTED BY FEB 9
Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were…

● Defense WorldOct 19, 2026 · 04:52 ET
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $304,272.41 in Stock

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) COO Julie Rubinstein sold 11,881 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average pric…

● GlobeNewsWireOct 14, 2026 · 16:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 9
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical pro…

● GuruFocusOct 12, 2026 · 18:49 ET
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100

On October 12, 2026, Adaptive Biotechnologies Corp (ADPT) shares fell 3.5%, currently trading at $25.57. The stock has seen significant volatility, with a 52-we…

● Defense WorldOct 12, 2026 · 02:15 ET
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) have received an average rating of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat Ratings repo…

● Defense WorldOct 6, 2026 · 10:00 ET
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy?

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $30.10 and last traded at $30.3490, with a volume of 2895 shar…

● GlobeNewsWireSep 25, 2026 · 08:03 ETCOMPANY'S OWN WORDS
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical pr…

● Defense WorldSep 24, 2026 · 04:15 ETEARNINGS EXPECTED BY FEB 9
Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)

Adaptive Biotechnologies (NASDAQ: ADPT - Get Free Report) and Charles River Laboratories International (NYSE: CRL - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the…

● Defense WorldSep 22, 2026 · 05:12 ET
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High – Should You Buy?

Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) shares hit a new 52-week high during trading on Tuesday. The company traded as high as $28.78 and last traded at $27.86, with a volume of 1458524 shar…

● GlobeNewsWireSep 17, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10 -6 sensitivity now preferred SE…

● Seeking AlphaSep 15, 2026 · 20:31 ET
Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript…

● GlobeNewsWireSep 1, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical pr…

● Defense WorldAug 29, 2026 · 04:00 ETEARNINGS EXPECTED BY FEB 9
Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT

Algert Global LLC decreased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 63.7% during a recent quarter, according to the company in its most recent filing with the SEC. The fund owned 131,830 sh…

● GeekWireAug 17, 2026 · 20:15 ET
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build massive datasets to decode…

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 9. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just ADPT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.